We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Representatives of the drug industry pounded the HHS Task Force on Drug Importation yesterday with their contention that it is impossible to ensure that imported drugs are safe and effective.
Mylan Laboratories apparently has finally escaped from its roller coaster ride in the multidistrict average wholesale price (AWP) litigation pending in a federal court in Massachusetts, the company announced yesterday.
Rather than looking to reimportation or price controls as solutions to the rising cost of prescription drugs, the U.S. should address the problem as a trade issue and work to ensure that European and other industrialized nations shoulder their fair share of the development burden, according to the Massachusetts Biotechnology Council (MBC).
In a move that could undercut generics already on the market, drugmaker Schering-Plough last week launched a generic version of its own hepatitis C drug Rebetol (ribavirin) at what some analysts expect will be a steeply discounted price.
High-ranking company officials will be required to certify the accuracy of the data their companies submit on average sales prices (ASPs), even though the Centers for Medicare & Medicaid Services’ (CMS) long-awaited interim final rule of the Medicare Prescription Drug, Improvement and Modernization Act does little to explain how to calculate ASP.
Faced with growing pressure in Congress on the issue of drug prices, the new chairman of PhRMA has announced a three-point platform that includes greater price transparency as part of an effort to help Americans lower their healthcare costs without resorting to drug reimportation or price controls.
Multiple generic firms started shipping versions of GlaxoSmithKline’s (GSK’s) antidepressant Wellbutrin SR (bupropion HCl extended- release) in 150-mg strength tablets last month after Andrx relinquished its 180-day exclusivity rights to the product.
Galen Holdings and Barr Pharmaceuticals have finalized deals that give Barr exclusive rights to Galen’s Loestrin oral contraceptive products and Galen the option to market Barr’s generic version of its own oral contraceptive Ovcon 35.
Despite unresolved patent issues, Teva Pharmaceutical on March 30 launched the first generic version of Purdue Pharma’s lucrative pain drug OxyContin (oxycodone) 80-mg strength extended-release tablets.
In the latest move against authorized generics, Mylan Laboratories has filed a lawsuit against rival Watson Pharmaceuticals and brand firm Procter & Gamble (P&G) over a deal that lets Watson market an authorized version of a P&G drug during Mylan’s 180-day marketing exclusivity period for the product.